Sanofi Quick Ratio 2010-2024 | SNY

Historical quick ratio values for Sanofi (SNY) over the last 10 years.
Sanofi Quick Ratio Historical Data
Date Current Assets - Inventory Current Liabilities Quick Ratio
2024-03-31 $0.00B 0.00
2023-12-31 $22.73B $26.19B 0.87
2023-09-30 $0.00B 0.00
2023-06-30 $21.82B $27.00B 0.81
2023-03-31 $0.00B 0.00
2022-12-31 $26.41B $25.25B 1.05
2022-09-30 $0.00B 0.00
2022-06-30 $7.91B $23.48B 0.34
2022-03-31 $0.00B 0.00
2021-09-30 $0.00B 0.00
2021-06-30 $24.39B $23.05B 1.06
2021-03-31 $0.00B 0.00
2020-09-30 $0.00B 0.00
2020-03-31 $0.00B 0.00
2019-09-30 $0.00B 0.00
2019-03-31 $0.00B 0.00
2018-03-31 $0.00B 0.00
2017-12-31 $22.08B $17.47B 1.26
2017-09-30 $0.00B 0.00
2017-06-30 $21.81B $18.76B 1.16
2017-03-31 $0.00B 0.00
2016-12-31 $21.91B $18.19B 1.21
2016-09-30 $0.00B 0.00
2016-06-30 $17.25B $17.22B 1.00
2016-03-31 $0.00B 0.00
2015-09-30 $0.00B 0.00
2015-06-30 $16.44B $18.03B 0.91
2014-06-30 $18.64B $19.48B 0.96
2013-06-30 $18.22B $17.80B 1.02
2012-06-30 $19.10B $20.66B 0.92
2012-03-31 $0.00B 0.00
2011-12-31 $20.62B $18.92B 1.09
2011-09-30 $0.00B 0.00
2011-06-30 $23.56B $23.10B 1.02
2011-03-31 $0.00B 0.00
2010-12-31 $29.29B $15.62B 1.88
2010-09-30 $0.00B 0.00
2010-06-30 $25.36B $15.40B 1.65
2010-03-31 $0.00B 0.00
2009-12-31 $27.10B $17.29B 1.57
2009-09-30 $0.00B 0.00
2009-06-30 $19.42B $14.69B 1.32
2009-03-31 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $119.456B $46.611B
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $847.248B 122.45
Novo Nordisk (NVO) Denmark $631.845B 48.55
Johnson & Johnson (JNJ) United States $350.533B 13.92
Merck (MRK) United States $324.174B 58.98
AbbVie (ABBV) United States $302.599B 15.64
AstraZeneca (AZN) United Kingdom $243.139B 21.14
Novartis AG (NVS) Switzerland $214.497B 15.21
Pfizer (PFE) United States $155.321B 19.30
Innoviva (INVA) United States $1.013B 7.11